EP Patent

EP3431603A1 — Antisense molecules and methods for treating pathologies

Assigned to University of Western Australia · Expires 2019-01-23 · 7y expired

What this patent protects

An antisense molecule capable of binding to a selected target site to induce skipping of exon 8 in the dystrophin gene

USPTO Abstract

An antisense molecule capable of binding to a selected target site to induce skipping of exon 8 in the dystrophin gene

Drugs covered by this patent

Patent Metadata

Patent number
EP3431603A1
Jurisdiction
EP
Classification
—
Expires
2019-01-23
Drug substance claim
No
Drug product claim
No
Assignee
University of Western Australia
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.